Floatz logo

HEPARIN

Angina

Nazareth HospitalmixtureN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Angina cohort.

Asset / SponsorPhaseRating
Ranolazine
East Carolina University
Phase 4A
Febuxostat
Takeda
Phase 2CCC
Auto-Cd34+ Cells
Foundation for Biomedical Research and Innovation
Phase 1/2CCC
DL-DOBUTAMINE
Wake Forest University Health Sciences
Early Phase 1C
REGADENOSON
Wake Forest University Health Sciences
Early Phase 1C
Acetylsalicylic Acid
Bayer
D

Same molecule, other indications

HEPARIN is also rated in:

venous thromboembolismDormant
BB
Indicative ·
67 / 100
View asset →
Insulin Resistance Syndrome XDormant
BB
Indicative ·
65 / 100
View asset →
Pancreatic Beta Cell FunctionDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →